Past Research Projects

Covid-19 Impact Surveys 

In 2020, Mesothelioma UK undertook two surveys to understand the impact of Covid-19 on patients and mesothelioma clinical nurse specialists, respectively.  

The initial survey was sent to patients in May 2020 and had 64 responders.  

Patients were asked about any impacts on their treatment schedule, hospital appointments and scans, the patient shielding list, contact with health care teams, and other areas affected by the pandemic. 

The key findings from the 64 responders to the survey include: 

  • 50% said their treatment had been affected including postponement of chemotherapy and entry onto clinical trials 
  • 64% said their scans or outpatient appointments had been changed, cancelled or postponed 
  • 52% automatically received a letter from the NHS advising them they were on the patient shielding list 
  • 28% experienced difficulty obtaining shopping including medicines 

 To read the full report click here 

The second survey was sent to Mesothelioma UK Clinical Nurse Specialists in September 2020. Twenty responses were received; they described in detail the challenges, fears and major concerns that have been directly derived from their experiences of caring for people living with mesothelioma through the Covid-19 pandemic.  

The key recommendation from this survey was that getting cancer treatment back on track for all is essential. To read the full report, click here.

Gendered Experience of Mesothelioma Study (GEMS)

The GEMS study aimed to explore the experiences of men and women with mesothelioma, their family carers as well as the various staff with whom they come into contact. 

GEMS was a Mesothelioma UK collaborative study supported by generous donations from 12 King’s Bench Walk, HASAG, Irwin Mitchell, Mesothelioma UK, Papworth Mesothelioma Social Group, and Royds Withy King. GEMS was conducted by the Mesothelioma Patient Experience Research Group at the School of Nursing and Midwifery, University of Sheffield. 

Researchers from the University of Sheffield carried out interviews with patients and key findings included: 

  • High risk occupations for men differed from high-risk occupations for women 
  • Women of all ages and younger men lacked awareness of the dangers of asbestos exposure 
  • Gender differences existed in the experiences of explanations and support provided at the time of diagnosis 
  • Men and women’s roles within the family and society influenced how they coped with a diagnosis of mesothelioma 
  • Men and women had different ways of communicating with professionals along the mesothelioma pathway 
  • Familial and social expectations of men and women influenced their willingness to pursue civil compensation 

 To read the full report, click here.

Healthcare Workers and Mesothelioma: Experiences of Presentation, Diagnosis, Treatment and Care: Healthcare Worker Mesothelioma Asbestos Guidance Study (MAGS) 

The MAGS study was carried out by researchers at the University of Sheffield and supported by donations from the family and friends of the late Dr Mags Portman, a pioneer in the fight to prevent and control HIV, who died of mesothelioma in 2019. 

With many NHS hospital buildings containing asbestos, the study aimed to explore the experiences of healthcare workers in the UK with mesothelioma and to develop recommendations for increasing awareness of the risk to healthcare workers. 

Recommendations from the study include the need to get a more accurate picture of the extent of mesothelioma amongst healthcare staff, that awareness of asbestos risk should be added to the mandatory training for new members of NHS staff, and that special consideration should be given to the communication of the diagnosis. 

Through patient interviews, literature reviews, and data analysis researchers examined the experiences of presentation, diagnosis, treatment, and care of healthcare staff with mesothelioma. Participants included both clinical staff, such as doctors and nurses, and non-clinical staff, such as medical secretaries, cleaners, porters, and maintenance staff. 

To read the full report, click here 

Military Experience of Mesothelioma Study: MIMES

A study carried out by researchers at the University of Sheffield, has detailed some of the experiences of, and support required for, armed forces personnel and military veterans with asbestos-related cancer. 

The Military Experiences of Mesothelioma Study (MiMES) aims to explore the prevalence of the asbestos-related cancer, mesothelioma among British armed forces veterans, to understand their experience and health/support needs, and to identify how health and legal professionals, and support agencies can best meet the needs of this group. 

2,700 new cases of mesothelioma are diagnosed in the UK each year and while the incidence among UK military veterans remains unknown, eight veterans per month claim war pensions due to a diagnosis of mesothelioma. 

The report identified the following key messages for healthcare and legal professionals, and other support agencies: 

  1. Assumptions regarding who has been exposed to asbestos while in the armed forces should be challenged and awareness of the risk of exposure should be raised
  2. Occupational history taking requires skill and sensitivity for patients with an armed forces background
  3. Veterans’ stoic approach may disguise their physical and emotional needs 
  4. Veterans require access to experts with experience of navigating the relevant health, legal and military systems 
  5. It is important to recognise and understand the perspective and support needs of family members
  6. Veterans living with mesothelioma may prefer to support, and be supported by, other veterans
  7. Some veterans see inequalities between their experience of living with mesothelioma and that of civilians 
  8. There is a lack of awareness regarding asbestos exposure in the armed forces and concern about ongoing asbestos risk 

To read the full report, click here 

Mesothelioma Patients’ Experiences of Follow-up Care across three NHS Trusts 

This grant was awarded in 2018 in partnership with Lung Cancer Nursing UK. The recipient of the grant was Dr Catherine Henshall, Senior Nursing Research Fellow at Oxford Brookes University, who carried out a study to identify best practice for patient follow-up care to help them to lead fulfilling lives and ‘live well’ with their condition. 

Dr Henshall’s study involved interviews with patients to identify any common themes around what constitutes living well. Studies involving patients with other long-term conditions have highlighted patients’ need for self-esteem and reliable professional and peer support, retaining personal responsibility and preserving identity. The study investigated if these findings apply to mesothelioma patients or if there are unique factors that enable them to live well. 

A New Approach for Personalising Therapy for Mesothelioma 

Awarded in 2015 in partnership with the British Lung Foundation, Professor Dean Fennell and his research team were granted £149,755 to research targeted, drug-based strategies for treating mesothelioma.  

It is now more than a decade since the original clinical trial that defined the only approved standard of care for patients with malignant pleural mesothelioma, i.e., pemetrexed and cisplatin chemotherapy. Following relapse after this treatment, unfortunately, there is no standard treatment option. This research will provide the scientific basis upon which to build a successful trial of a new drug candidate in mesothelioma, called a CDK4/6 inhibitor. 

Addressing Hypoxia as a New Target for Treatment of Asbestos-induced Cancer 

Awarded in 2016 in partnership with the British Lung Foundation, Professor Marija Krstic-Demonacos was granted £ 111,750 to research the role of low oxygen in mesothelioma.  

The role of hypoxia (low oxygen) in cancer has been extensively studied and this has disclosed intriguing insights into how low oxygen levels favour cancer development and progression. This study will investigate the consequences of low oxygen levels in mesothelioma and develop a new class of drug that tackles these, hopefully stopping cancer growth. 

MEDUSA:  Mesothelioma Evolution: Deciphering drUgable somatic alterations as potential targets for synthetic lethal therapy 

Awarded in 2017 in partnership with the British Lung Foundation, Dr Edward Hollox was granted £149,930 to investigate the genetic mutations that drive mesothelioma.  

This study aims to discover more about the genetic mutations that drive mesothelioma, and how these evolve over time and in different parts of a tumour. This will help identify new targets for the development of a range of new drugs that will hopefully kill all cancerous cells and prevent relapse. 

You can read the full report here. 

Non-Invasive Diagnosis of Mesothelioma using Structured Light Plethysmography 

Commission in 2017 with support from Pat Stone Mesothelioma Support and in partnership with Lung Cancer Nursing UK.   

Amy Kerr conducted research into a new diagnosis method called structured light plethysmography (SLP)SLP is a new diagnosis method which measures chest wall motion which can highlight differences according to the disease which is causing abnormalities on chest X rays or CT scans.  

The results showed that SLP could not tell the difference between people with mesothelioma and those without it with enough accuracy for doctors to be confident of the diagnosis. We concluded that SLP should not be added to the tests to help diagnose mesothelioma. Patients found the test easy and acceptable so there may still be a use for chest movements to monitor patients with mesothelioma as they have treatment, this would need further research.  

You can read the full report here.